Innovation Pharmaceuticals has reported positive top-line results from a Phase II clinical trial of brilacidin in patients with inflammatory bowel disease (IBD) types known as ulcerative proctitis and ulcerative proctosigmoiditis (UP/UPS).

Brilacidin is a non-corticosteroid, non-biologic treatment being formulated as tablets for ulcerative colitis and Crohn’s Disease, and as foam and/or gel for UP/UPS.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The results from the open-label, proof-of-concept (PoC) trial showed that the investigational candidate achieved clinical remission in the majority of patients with mild-to-moderate UP/UPS.

The remission rates were found to be similar across all the three cohorts of the Phase II trial.

Innovation Pharmaceuticals president and chief medical officer Arthur Bertolino said: “To see such strong results with a basic formulation adds further credibility to where we believe we can take brilacidin in treating the full continuum of IBD, particularly when optimally formulated and administered.

"Combined with the brilacidin data for treating oral mucositis as a preventative medicine, we now have two solid anchors supporting brilacidin’s considerable and diverse therapeutic potential."

“Combined with the brilacidin data for treating oral mucositis as a preventative medicine, we now have two solid anchors supporting brilacidin’s considerable and diverse therapeutic potential.”

Brilacidin was evaluated as a once-daily retention enema formulation of 50mg, 100mg and 200mg over a period of 42 days, with clinical remission at day 42 as the trial's primary efficacy endpoint.

The trial’s secondary efficacy endpoints included a change in both full and partial MMDAI score and change in patient quality-of-life as measured by the short inflammatory bowel disease questionnaire (SIBDQ).

The trial demonstrated improvement in quality-of-life, as well as favourable tolerability without any serious adverse events (SAEs).